Advanced Search

 

Study ID Status Title Patient Level Data
CRH103390 Completed Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
CRH108571 Completed Double-blind, randomized, placebo and Alprazolam-controlled three-period crossover incomplete block design study to compare putative anxiolytic-like fRMI activity of GW876008 and GSK561679 after single-dose administration in subjects with Social Anxiety Disorder (SAD)
CRI103143 Completed A phase IIa pharmacodynamic study of antagonism of irritable bowel syndrome (IBS) symptoms by GW876008, a corticotrophin releasing factor 1 receptor antagonist (CRF1-RA)
CRI105626 Completed A Phase 2 PoC in IBS patients with the CRF1 receptor anatgonist, GSK876008
CRR110744 Completed Phase I, open label drug-drug interaction study in healthy volunteers to evaluate the effect of KALETRA (lopinavir-ritonavir) on GSK706769 pharmacokinetics and to evaluate the pharmacokinetics of a new oral formulation of GSK706769
CRR111382 Completed A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects
CRS105510 Completed A randomised, placebo-controlled, double-dummy, crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GSK561679 and lorazepam (comparator) in healthy subjects
CRS105511 Completed Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone with a single dose of GSK561679 or Alprazolam in Healthy Volunteers
CRV110734 Completed A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure- An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study) Study Listed on ClinicalStudyDataRequest.com
CRZ107432 Completed A single blind, randomized, placebo controlled, crossover study to investigate the safety, tolerability and pharmacokinetics of single oral escalating doses of GSK586529 in healthy volunteers
CUC111342 Terminated An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis. Study Listed on ClinicalStudyDataRequest.com
CXA10017 Completed An open-label, non-randomised, single sequence study to investigate the effect of a New Chemical Entity (NCE) on the pharmacokinetic profile of digoxin in healthy subjects.
CXA100754 Completed An open-label, non-randomised study of 20 mg GW406381 single dose pharmacokinetics in healthy subjects and in volunteers with moderate hepatic impairment
CXA30007 Completed A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered orally once daily, in adults with Osteoarthritis of the knee.
CXA30009 Completed A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis
D2250298 Completed An irritation patch test of topical formulations containing aciclovir
D-23129-8001/8005/ 8017 Completed Long term efficacy and safety of orally administered D-23129 in patients with partial onset seizures (long-term extension of studies 8001 [200] and 8005 [201])
D-23129-8040 Completed Clinical trial to assess tolerability, safety and efficacy of orally administered retigabine in patients with bipolar affective disorders (acute mania). Open pilot study with a sequential group design
DAN106587 Completed A placebo controlled, single blind, randomised study investigating the safety, tolerability and Pharmacokinetics of repeated oral doses of GSK598809 in healthy male and female volunteers for 28 days.
DAN106593 Completed A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Study Listed on ClinicalStudyDataRequest.com
DAN107606 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses of GSK598809 in smokers
DAN111282 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses (75mg and above) of GSK598809 in otherwise healthy smokers
DAN111283 Completed An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of a 100mg capsule compared to four 25mg GSK598809 capsules and the effect of food on the pharmacokinetics of the 100mg capsule in healthy male and female volunteers.
DB1111509 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
DB1111581 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.